Trodelvy Market Report 2026

Trodelvy Market Overview

• The Trodelvy market growth in the historic period has been driven by increasing incidence of metastatic breast cancer, advancements in monoclonal antibody engineering • Market expansion is supported by expansion of personalized cancer treatment protocols, rising investments in adc pipeline development • Growth Driver: Increase In Breast Cancer Incidence Driving Market Growth Due To Rising Diagnosis Rates And Advances In Treatment Options • Market Trend: Trodelvy Expands Market With HR-Positive, HER2-Negative Breast Cancer Approval • North America was the largest region in 2025.

What Is Covered Under Trodelvy Market?

Trodelvy is an antibody-drug conjugate (ADC) that combines a targeted monoclonal antibody with a chemotherapy agent. The monoclonal antibody binds to Trop-2, a protein often overexpressed in specific cancer cells, delivering the chemotherapy directly to these cells. The main indications in the trodelvy market are metastatic triple-negative breast cancer (mTNBC), HR+ or HER2-negative breast cancer, and metastatic urothelial cancer. Metastatic triple-negative breast cancer (mTNBC) refers to a subtype of breast cancer that is negative for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). The various distribution channels include hospitals and clinics and retail and specialty pharmacies, and several end users encompass adult patients and geriatric patients.

What Is The Trodelvy Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of personalized cancer treatment protocols, rising investments in adc pipeline development, increasing use of biomarker-driven therapies, advancements in linker and payload technologies, growing demand for improved cancer survival outcomes. Major trends in the forecast period include increasing adoption of antibody drug conjugate therapies, rising focus on targeted oncology treatments, expansion of trop-2 targeted therapeutics, growing use of precision oncology approaches, enhanced drug delivery mechanisms.

Global Trodelvy Market Segmentation

1) By Indication: Metastatic Triple-Negative Breast Cancer (mTNBC), HR+ Or HER2-Negative Breast Cancer, Metastatic Urothelial Cancer 2) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies 3) By End User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Trodelvy Market?

The increase in the incidence of breast cancer is expected to propel the growth of the trodelvy market going forward. Breast cancer is a disease in which malignant (cancerous) cells form in the tissues of the breast. It is one of the most common cancers worldwide and affects both women and, less commonly, men. The increase in the incidence of breast cancer is attributed to genetic predisposition, lifestyle changes, and increased awareness, leading to greater investments in advanced treatment options and healthcare infrastructure globally. Trodelvy is helpful for breast cancer patients by providing effective targeted treatment for advanced or metastatic cases, helping improve survival outcomes, and addressing the increasing healthcare needs associated with the high incidence of breast cancer. For instance, in 2024, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, around 313,510 new cases of breast cancer were diagnosed, an increase compared to 300,590 cases reported in 2023. Therefore, the high incidence of breast cancer is driving the growth of the trodelvy industry. The increase in the incidence of chronic diseases is expected to propel the growth of the trodelvy market going forward. Chronic diseases refer to long-lasting health conditions that typically cannot be cured but can often be managed, such as cancer, cardiovascular disorders, and metabolic conditions, often require long-term and specialized treatments, including advanced targeted therapies. This rise in chronic disease incidence is driven by aging populations, sedentary lifestyles, unhealthy diets, and environmental risk factors. The increasing prevalence of chronic diseases supports the trodelvy by boosting demand for innovative oncology therapies that provide precise targeting of tumor cells, reduce side effects, and improve patient outcomes. For instance, in April 2025, according to the NHS Confederation, a UK-based national association, in 2035, it is estimated that 17% of the UK population could be living with four or more chronic conditions. Therefore, the increase in the incidence of chronic diseases is driving the growth of the trodelvy industry.

Key Players In The Global Trodelvy Market

Major companies operating in the trodelvy market are Gilead Sciences Inc.

Global Trodelvy Market Trends and Insights

Key Companies are operating in the trodelvy market are expanding treatment indications to provide a broader range of patients with advanced, targeted therapies that improve survival outcomes and quality of life. This strategy addresses unmet medical needs in multiple oncology indications, enhancing the drug’s clinical impact and commercial potential across diverse patient populations. For instance, in February 2023, Gilead Sciences Inc., a US-based pharmaceutics company, secured expanded United States approval for Trodelvy to treat HR-positive and HER2-negative metastatic breast cancer, significantly widening the market and addressing a larger patient population. This marks a strategic advancement for trodelvy, positioning it to compete more effectively in the broader breast cancer treatment landscape.

Regional Insights

North America was the largest region in the trodelvy market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Trodelvy Market?

The trodelvy market consists of sales of companion diagnostic tests and antibody-drug conjugates, and adjunctive therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Trodelvy Market Report 2026?

The trodelvy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the trodelvy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.